No Data
No Data
Stifel Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $27
Express News | IGM Biosciences Inc : Stifel Raises Target Price to $27 From $25
RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development
IGM Biosciences Shifts Focus to Autoimmunity
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates
No Data
No Data